CD274 and non-small cell lung carcinoma: First-line therapy for non-small-cell lung cancer using combination nivolumab plus ipilimumab in patients with a PD-L1 expression level of 1% or more, shows a median overall survival of 17.1 months and 15.7 months with nivolumab alone [HR 0.90 (0.76–1.07)] and a 2 year overall survival rate of 40.0 and 36%, respectively.